Early Detection of Arteriosclerosis

NCT ID: NCT00863967

Last Updated: 2009-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

269 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-10-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Arteriosclerosis is a common chronic disease with well known risk factors like diabetes mellitus, hypertension, dyslipidemia, adipositas and smoking, leading to severe complications like myocardial infarction, stroke or peripheral arterial occlusive disease. In addition to life-style factors there is also a genetic predisposition to develop complicated atherosclerosis.

Objective: Improve individual risk prediction by clinical phenotyping and genotyping.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

About 300 patients who are treated for various conditions at the department of general medicine at our hospital will be included prospectively in the study. This observational cohort will be followed for at least 10 years follow-up examinations.

At baseline and during follow up visits detailed clinical phenotyping is planned (medical and family history,standardized clinical and physical examinations, lab, RX, ECG, stress-test or echocardiogram). The genotyping is performed by DNA-isolation from leucocytes collected at baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriosclerosis Atherosclerosis Myocardial Infarction Stroke Diabetes Mellitus Peripheral Arterial Occlusive Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

no cardiovascular events

No interventions assigned to this group

2

proven cardiovascular events

No interventions assigned to this group

3

possible cardiovascular events

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and older
* informed consent

Exclusion Criteria

* life-threatening disease
* life expectancy \< 1 month
* uncapable to provide informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kantonsspital Baselland Bruderholz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of medicine, Kantonsspital Bruderholz, CH-4101 Bruderholz

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara Biedermann, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Department Kantonsspital Bruderholz CH-4101 Bruderholz

References

Explore related publications, articles, or registry entries linked to this study.

Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002 Jun 15;359(9323):2078-83. doi: 10.1016/S0140-6736(02)08907-9.

Reference Type BACKGROUND
PMID: 12086762 (View on PubMed)

Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002 Nov;8(11):1218-26. doi: 10.1038/nm1102-1218. No abstract available.

Reference Type BACKGROUND
PMID: 12411948 (View on PubMed)

Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002 Jul 18;347(3):185-92. doi: 10.1056/NEJMoa012673.

Reference Type BACKGROUND
PMID: 12124407 (View on PubMed)

Nabel EG. Cardiovascular disease. N Engl J Med. 2003 Jul 3;349(1):60-72. doi: 10.1056/NEJMra035098. No abstract available.

Reference Type BACKGROUND
PMID: 12840094 (View on PubMed)

Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002 Feb 5;105(5):570-5. doi: 10.1161/hc0502.103348.

Reference Type BACKGROUND
PMID: 11827921 (View on PubMed)

Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115-26. doi: 10.1056/NEJM199901143400207. No abstract available.

Reference Type BACKGROUND
PMID: 9887164 (View on PubMed)

Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3893-7. doi: 10.1073/pnas.92.9.3893.

Reference Type BACKGROUND
PMID: 7732003 (View on PubMed)

Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman WP 3rd, Herderick EE, Cornhill JF. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999 Feb 24;281(8):727-35. doi: 10.1001/jama.281.8.727.

Reference Type BACKGROUND
PMID: 10052443 (View on PubMed)

Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002 Dec 12;347(24):1916-23. doi: 10.1056/NEJMoa021445.

Reference Type BACKGROUND
PMID: 12477941 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KSBH: 216/03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.